Brilliant blue g - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for brilliant blue g and what is the scope of patent protection?
Brilliant blue g
is the generic ingredient in one branded drug marketed by Dutch Ophthalmic and is included in one NDA. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for brilliant blue g
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 91 |
| Clinical Trials: | 6 |
| Patent Applications: | 2,398 |
| What excipients (inactive ingredients) are in brilliant blue g? | brilliant blue g excipients list |
| DailyMed Link: | brilliant blue g at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brilliant blue g
Generic Entry Date for brilliant blue g*:
Constraining patent/regulatory exclusivity:
INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) Dosage:
SOLUTION;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for brilliant blue g
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Anthera Pharmaceuticals | Phase 3 |
| Asociación para Evitar la Ceguera en México | Phase 3 |
Pharmacology for brilliant blue g
| Drug Class | Disclosing Agent |
| Mechanism of Action | Dyes |
US Patents and Regulatory Information for brilliant blue g
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dutch Ophthalmic | TISSUEBLUE | brilliant blue g | SOLUTION;OPHTHALMIC | 209569-001 | Dec 20, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Dutch Ophthalmic | TISSUEBLUE | brilliant blue g | SOLUTION;OPHTHALMIC | 209569-001 | Dec 20, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
